AMLX — Amylyx Pharmaceuticals, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1658551 ·
Last close
$27.20
Market Cap
$3.03B
52W High
$41.14
52W Low
$10.83
ADV30
1,552,785
Next earnings
2026-11-05
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -45,693,000 | -43,423,000 | 264,564,000 | 49,326,000 | 25,397,000 |
| Mar 2026 | 0 | 0 | -43,779,000 | -41,284,000 | 293,603,000 | 229,136,000 | 20,442,000 |
| Dec 2025 | 0 | 0 | -36,605,000 | -32,999,000 | 332,645,000 | 226,651,000 | 27,386,000 |
| Sep 2025 | 0 | 0 | -36,027,000 | -34,386,000 | 362,741,000 | 225,178,000 | 30,745,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-126,577,000
Investing CF
$-78,831,000
Financing CF
$196,094,000
CapEx
$-138,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.43
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-836,134,000
Inventory
$0
Receivables
$88,000
ST Investments
$201,434,000
EBIT TTM
$-162,104,000
Pretax Income TTM
$-152,046,000
Interest Exp TTM
—
Analysts
9
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -153,291,000 | -144,735,000 | 332,645,000 | 27,386,000 | 305,259,000 | -123,343,000 |
| Dec 2024 | 87,371,000 | -255,677,000 | -301,743,000 | 193,634,000 | 28,869,000 | 164,765,000 | -167,647,000 |
| Dec 2023 | 380,786,000 | 38,802,000 | 49,271,000 | 517,454,000 | 84,022,000 | 433,432,000 | 11,919,000 |
| Dec 2022 | 22,230,000 | -201,341,000 | -198,375,000 | 391,453,000 | 50,846,000 | 340,607,000 | -179,871,000 |
TTM Snapshot
Revenues TTM
$2,570,000
NetIncome TTM
$-150,112,000
OpCashFlow TTM
—
Assets (Latest)
$293,603,000
Forward EPS
$-1.15
Max Pain — expiry 2026-10-16
max pain strike: $35.00 · spot: $28.14 · call oi: 2,670 · put oi: 2,402Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| DYN | Dyne Therapeutics, Inc. | $3.06B | $16.37 | — |
| RCUS | Arcus Biosciences, Inc. | $3.00B | $23.83 | — |
| ARQT | Arcutis Biotherapeutics, Inc. | $3.08B | $24.49 | — |
| ELVN | Enliven Therapeutics, Inc. | $2.98B | $40.63 | — |
| VKTX | Viking Therapeutics, Inc. | $3.23B | $27.73 | — |
News headlines (Yahoo Finance, 1h cache)
Amylyx Pharmaceuticals to Present Topline Data from Phase 3 LUCIDITY Clinical Trial of Avexitide in Post-Bariatric Hypoglycemia at ObesityWeek® 2026 Annual Meeting
2026-10-06 12:00 · Yahoo
Amylyx Pharmaceuticals And 2 More Quality Growth Stocks
2026-10-04 07:09 · Yahoo
Amylyx's Avexitide Phase III Win Sets Up FDA Filing for PBH Treatment
2026-10-03 07:02 · Yahoo
Amylyx Pharmaceuticals to Present at the Stifel 2026 Virtual Cardiometabolic Forum
2026-09-23 13:00 · Yahoo
Tortugas Neuroscience Announces Appointment of Jim Frates to Board of Directors
2026-09-09 12:00 · Yahoo
Amylyx Pharmaceuticals to Present at the 24th Annual Morgan Stanley Global Healthcare Conference
2026-09-08 13:00 · Yahoo
Is GLP-1 Stock Amylyx Still a Buy After Skyrocketing 247%?
2026-09-01 13:50 · Yahoo
Why Amylyx Pharmaceuticals Blasted Nearly 79% Higher This Week
2026-08-21 22:00 · Yahoo
Amylyx (AMLX) Faces a Binary Phase 3 Test. Can Avexitide Rebuild the Company?
2026-08-21 21:58 · Yahoo
Why Did IOVA, AMLX And COP Stocks Surge To 52-Week Highs Today?
2026-08-21 03:57 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.